Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195771 | 0.86 | BIRC5 (0.62) | CYP2A6PDGFRBPDGFRAPIK3CAPIK3CD | |
| SCHEMBL29449763 | 0.82 | PDGFRB (0.64) | CYP2A6PDGFRBPDGFRAPIK3CAPIK3CD | |
| SCHEMBL28633433 | 0.82 | PDGFRB (0.64) | CYP2A6PDGFRBPDGFRAPIK3CAPIK3CD | |
| SCHEMBL2111139 | 0.82 | KDM4E (0.58) | PDGFRBPDGFRAKDM4EKDRCYP1A2 | |
| SCHEMBL4185498 | 0.81 | TDP2 (0.59) | CYP2A6PDGFRBPDGFRAPIK3CAPIK3CD | |
| SCHEMBL4192415 | 0.80 | XDH (0.59) | XDHSLC22A12CNR1MKNK2 | |
| SCHEMBL2772360 | 0.78 | PDGFRB (0.77) | CYP2A6PDGFRBPDGFRAPIK3CAPIK3CD | |
| SCHEMBL32667946 | 0.78 | PDGFRB (0.77) | CYP2A6PDGFRBPDGFRAPIK3CAPIK3CD | |
| SCHEMBL4194226 | 0.77 | CYP1A2 (0.55) | CYP2A6PDGFRBPDGFRAPIK3CAPIK3CD | |
| SCHEMBL17742433 | 0.77 | IGF1R (0.51) | PDGFRBPDGFRABIRC5CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006072792-A2 | COMPOUNDS WHICH BIND TO THE ACTIVE SITE OF PROTEIN KINASE ENZYMES | GALAPAGOS NV (BE) | 2006-07-13 | — | — | WO | disclosed |
| EP-1644365-A2 | PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS | Biofocus Discovery Ltd (GB) | 2006-04-12 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005003101-A2 | PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS | BIOFOCUS DISCOVERY LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004085409-A2 | COMPOUNDS AND LIBRARIES OF PYRIDINES, PYRAZINES, IMIDAZO[1,2-A]PYRAZINES AND 1H-IMIDAZO[4,5-B]PYRAZIN-2-ONES AND FIRST AND SECOND MEDICAL USES THEREOF | BIOFOCUS DISCOVERY LTD (GB) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | CYP2A6 2233/4885PDGFRB 1244/4885PDGFRA 1484/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | CYP2A6 1880/4885PDGFRB 4237/4885PDGFRA 4611/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CYP2A6 1880/4885PDGFRB 4237/4885PDGFRA 4611/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CYP2A6 1880/4885PDGFRB 4237/4885PDGFRA 4611/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | CYP2A6 1615/4885PDGFRB 614/4885PDGFRA 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.